Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis
Caitlyn Harvey, Sinéad Weldon, J.S. Elborn, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3513-3513
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Role of inhaled antibiotics in the era of highly effective CFTR modulators
J.S. Elborn, Francesco Blasi, Pierre–Régis Burgel, et al.
European Respiratory Review (2023) Vol. 32, Iss. 167, pp. 220154-220154
Open Access | Times Cited: 30
Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease
Janis K. Shute
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 584-584
Open Access | Times Cited: 23
Eradication of Mycobacterium abscessus infection in cystic fibrosis with initiation of Elexacaftor/Tezacaftor/Ivacaftor
Caoimhe McParland, Matthew Nunn, Theodore K. Marras, et al.
Journal of Cystic Fibrosis (2023) Vol. 23, Iss. 1, pp. 38-40
Closed Access | Times Cited: 14
Inflammation as a Regulator of the Airway Surface Liquid pH in Cystic Fibrosis
Tayyab Rehman, Michael J. Welsh
Cells (2023) Vol. 12, Iss. 8, pp. 1104-1104
Open Access | Times Cited: 13
Clinical and radiological improvement of cavitary Mycobacteroides abscessus disease in cystic fibrosis following initiation of elexacaftor/tezacaftor/ivacaftor
Roderick Gavey, J D Nolan, Vanessa Moore, et al.
Journal of Cystic Fibrosis (2024) Vol. 23, Iss. 5, pp. 1024-1026
Open Access | Times Cited: 5
Longitudinal Study on Clinical Predictors for Allergic Bronchopulmonary Aspergillosis in Children and Young People with Cystic Fibrosis Highlights the Impact of Infection with Aspergillus and Pseudomonas and Ivacaftor Treatment
Emily Chesshyre, Beth Enderby, Angela C. Shore, et al.
Journal of Fungi (2025) Vol. 11, Iss. 2, pp. 116-116
Open Access
Unraveling the Mechanism of Action, Binding Sites, and Therapeutic Advances of CFTR Modulators: A Narrative Review
Debora Baroni
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 2, pp. 119-119
Open Access
The CFTR K464N variant in fetuses potential increases premature birth risk in Chinese families
Jingping Li, Lingyun Zhang, Fangfang Xi, et al.
Human Genomics (2025) Vol. 19, Iss. 1
Open Access
Esc peptides and derivatives potentiate the activity of CFTR with gating defects and display antipseudomonal activity in cystic fibrosis-like lung disease
Loretta Ferrera, Floriana Cappiello, Arianna Venturini, et al.
Cellular and Molecular Life Sciences (2025) Vol. 82, Iss. 1
Open Access
The impact of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on the pulmonary microbiota
Joshua K. Robertson, Joanna B. Goldberg
Microbiology (2025) Vol. 171, Iss. 4
Closed Access
Fungal Colonization of the Airways of Patients with Cystic Fibrosis: the Role of the Environmental Reservoirs
Kévin Ravenel, Hélène Guegan, Amandine Gastebois, et al.
Mycopathologia (2024) Vol. 189, Iss. 2
Closed Access | Times Cited: 4
Antibacterial and Antibiofilm Effects of Lactobacilli Strains against Clinical Isolates of Pseudomonas aeruginosa under Conditions Relevant to Cystic Fibrosis
Giovanna Batoni, Elisa Catelli, Esingül Kaya, et al.
Antibiotics (2023) Vol. 12, Iss. 7, pp. 1158-1158
Open Access | Times Cited: 10
Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations
Christina S. Thornton, Lindsay J. Caverly, Linda M. Kalikin, et al.
Annals of the American Thoracic Society (2023) Vol. 21, Iss. 4, pp. 595-603
Closed Access | Times Cited: 9
Role of viable but non culturable cells in patients with cystic fibrosis in the era of highly effective modulator therapy
Natalia Cirilli, Valentina Schiavoni, Valentina Tagliabracci, et al.
Journal of Cystic Fibrosis (2024)
Open Access | Times Cited: 2
Akt-driven TGF-β and DKK1 Secretion Impairs F508del Cystic Fibrosis Airway Epithelium Polarity
Tahir Idris, Michaël Bachmann, Matthew Bacchetta, et al.
American Journal of Respiratory Cell and Molecular Biology (2024) Vol. 71, Iss. 1, pp. 81-94
Closed Access | Times Cited: 2
Mutational spectrum of CFTR in cystic fibrosis patients with gastrointestinal and hepatobiliary manifestations
Nadia Waheed, Rehmana Waris, Maryam Naseer, et al.
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access | Times Cited: 2
Changing profile of bacterial infection and microbiome in cystic fibrosis: when to use antibiotics in the era of CFTR-modulator therapy
Justyna Milczewska, Zulfiya Syunyaeva, Aleksandra Żabińska-Jaroń, et al.
European Respiratory Review (2024) Vol. 33, Iss. 174, pp. 240068-240068
Open Access | Times Cited: 2
Genetic attributes of Iranian cystic fibrosis patients: the diagnostic efficiency of CFTR mutations in over a decade
Amin Hosseini Nami, Mahboubeh Kabiri, Fatemeh Zafarghandi Motlagh, et al.
Frontiers in Genetics (2023) Vol. 14
Open Access | Times Cited: 6
Bile effects on the Pseudomonas aeruginosa pathogenesis in cystic fibrosis patients with gastroesophageal reflux
Mobina Bayat, Javid Sadri Nahand, Nader Farsad-Akhatr, et al.
Heliyon (2023) Vol. 9, Iss. 11, pp. e22111-e22111
Open Access | Times Cited: 6
Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa
Ronan A. Murphy, Matthew Coates, Sophia Thrane, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 4
Open Access | Times Cited: 9
Exoproducts of the Most Common Achromobacter Species in Cystic Fibrosis Evoke Similar Inflammatory Responses In Vitro
Cecilia Sahl, Maria Baumgarten, Oonagh Shannon, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 4
Open Access | Times Cited: 5
Longitudinal bacterial prevalence in cystic fibrosis airways: Fact and artifact
Donald R. VanDevanter, John J. LiPuma, Michael W. Konstan
Journal of Cystic Fibrosis (2023) Vol. 23, Iss. 1, pp. 58-64
Closed Access | Times Cited: 5
Exhaled Breath Analysis Detects the Clearance of Staphylococcus aureus from the Airways of Children with Cystic Fibrosis
Elias Seidl, Johann-Christoph Licht, Rianne de Vries, et al.
Biomedicines (2024) Vol. 12, Iss. 2, pp. 431-431
Open Access | Times Cited: 1
Phage therapy to treat cystic fibrosis Burkholderia cepacia complex lung infections: perspectives and challenges
Jack S. Canning, Daniel R. Laucirica, Kak‐Ming Ling, et al.
Frontiers in Microbiology (2024) Vol. 15
Open Access | Times Cited: 1
A new era in cystic fibrosis care: always changing and adapting
Barry Lawrence Diener, Fredy Huertero, Teresa Stables‐Carney, et al.
Current Opinion in Pediatrics (2023) Vol. 35, Iss. 5, pp. 603-610
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top